Inozyme Pharma Inc. Announces Delisting from Nasdaq and Deregistration of Shares Following Merger
Inozyme Pharma Inc. has announced its delisting from Nasdaq and deregistration of shares following a merger, effective July 1, 2025. The company has requested Nasdaq to file a Form 25 with the SEC to remove its shares from listing and intends to file a Form 15 to terminate registration and suspend reporting obligations under the Securities Exchange Act of 1934. This marks a significant regulatory move in Inozyme's corporate trajectory post-merger.
Inozyme Pharma Inc. has announced a significant regulatory move involving its shares. Effective July 1, 2025, the company notified the Nasdaq Global Select Market of the completion of a merger, leading to the suspension of trading and delisting of its shares. Inozyme has requested Nasdaq to file a Form 25 with the SEC to remove the shares from listing and deregister them under the Securities Exchange Act of 1934. The company also intends to file a Form 15 with the SEC to terminate the registration of its shares and suspend reporting obligations under certain sections of the Exchange Act. This strategic decision marks a key development in Inozyme’s corporate trajectory following the consummation of a merger. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inozyme Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-153582), on July 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
